---
{"dg-publish":true,"permalink":"/entities/biomarker/triglycerides/","tags":["biomarker"]}
---

# Triglycerides

## Overview
No description available.

## Reference Ranges
Reference ranges not available.


## Testing Information
- **Measurement Unit**: Not specified
- **Sample Type**: Not specified
- **Fasting Required**: False
- **Recommended Test Frequency**: Not specified



## Relationships

### Influences
No known influences documented.

### Correlations
No correlations documented.

### Other Relationships
### Related
- ‚Üí [[Omega-3_Fatty_Acids\|Omega-3_Fatty_Acids]] (entity)
```yaml
last_modified: '2026-01-19T09:30:28.888881'
source: obsidian
```
- ‚Üí [[entities/drug/Berberine\|Berberine]] (drug)
```yaml
last_modified: '2026-01-19T09:30:28.888881'
source: obsidian
```
- ‚Üí [[entities/biomarker/Triglycerides\|Triglycerides]] (biomarker)
```yaml
last_modified: '2026-01-19T09:30:28.888881'
source: obsidian
```
- ‚Üê [[entities/drug/Berberine\|Berberine]] (supplement)
```yaml
last_modified: '2026-01-19T09:06:58.948673'
source: obsidian
```
- ‚Üê [[Omega-3_Fatty_Acids\|Omega-3_Fatty_Acids]] (supplement)
```yaml
last_modified: '2026-01-19T09:07:12.965838'
source: obsidian
```
- ‚Üí [[Cardiovascular_Risk_Pattern\|Cardiovascular_Risk_Pattern]] (entity)
```yaml
last_modified: '2026-01-19T09:30:28.888881'
source: obsidian
```
- ‚Üí [[Insulin_Resistance\|Insulin_Resistance]] (entity)
```yaml
last_modified: '2026-01-19T09:30:28.888881'
source: obsidian
```
- ‚Üí [[Metabolic_Syndrome\|Metabolic_Syndrome]] (entity)
```yaml
last_modified: '2026-01-19T09:30:28.888881'
source: obsidian
```
- ‚Üê [[Cardiovascular_Risk_Pattern\|Cardiovascular_Risk_Pattern]] (clinicalpattern)
```yaml
last_modified: '2026-01-19T09:30:37.203726'
source: obsidian
```
- ‚Üê [[Insulin_Resistance\|Insulin_Resistance]] (condition)
```yaml
last_modified: '2026-01-19T09:31:13.820465'
source: obsidian
```
- ‚Üê [[Metabolic_Syndrome\|Metabolic_Syndrome]] (condition)
```yaml
last_modified: '2026-01-19T09:31:23.144461'
source: obsidian
```
- ‚Üê [[entities/drug/Berberine\|Berberine]] (drug)
```yaml
last_modified: '2026-01-19T09:31:50.148655'
source: obsidian
```

### Requires Biomarker
- ‚Üê [[Cardiovascular_Risk_Pattern\|Cardiovascular_Risk_Pattern]] (clinicalpattern)
```yaml
last_modified: '2026-01-19T09:30:36.399745'
source: obsidian
```
- ‚Üê [[Insulin_Resistance\|Insulin_Resistance]] (condition)
```yaml
last_modified: '2026-01-19T09:30:38.659417'
source: obsidian
```
- ‚Üê [[Metabolic_Syndrome\|Metabolic_Syndrome]] (condition)
```yaml
last_modified: '2026-01-19T09:30:42.706915'
source: obsidian
```

### Decreases Biomarker
- ‚Üê [[Omega-3_Fatty_Acids\|Omega-3_Fatty_Acids]] (supplement)
```yaml
effect_direction: decreases
evidence_level: 5
last_modified: '2026-01-19T09:07:12.526277'
magnitude: strong
magnitude_range: 25-30% reduction
notes: FDA-approved for hypertriglyceridemia at 4g/day. Dose-response relationship
  well established.
onset_timeframe: 4-12 weeks
population_context: elevated triglycerides
source: obsidian
study_references:
- PMID:30586774
- PMID:31422671
```

## üíä Supplements That Affect This Biomarker

- [[entities/Supplement/Omega-3 Fatty Acids\|Omega-3 Fatty Acids]] - Decreases triglycerides 25-30% (evidence level 5, FDA-approved)

## üß™ Lab Tests That Measure This Biomarker

### Direct Tests
- [[entities/biomarker/Triglycerides\|triglycerides]] - Direct triglyceride measurement

### Panel Tests
- [[entities/labtest/lipid panel standard\|lipid panel standard]] - Standard lipid panel
- [[entities/labtest/advanced lipid panel\|advanced lipid panel]] - Advanced lipid panel

## References
No references available.

## Dataview Queries

{ .block-language-dataview}